NCT03655002 2025-06-17
IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
Clinical Trials
3 trialsNCT03758781 2023-04-14
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03575234 2019-08-28
Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer
Emory University
Phase 1 Withdrawn